IPNews® – The Federal Circuit on Tuesday partially reversed a lower court’s finding that a number of Santarus Inc.’s patent claims for its heartburn drug Zegerid are invalid, giving Santarus another crack at hanging Par Pharmaceuticals Inc. out to dry for trying to market a generic version of the drug.

The district court slipped up…